Lund, Sweden – 01 June – Asgard Therapeutics AB (“Asgard”) today announces that the United States...
Read moreAsgard Therapeutics announces today that the Eurostars-funded project REPRogramming tumors INTo immune cells - a revolutionary gene therapy to treat cancer (REPRINT) - has officially kicked-off.
Read moreThe world wealthiest look for cellular reprogramming as the key for longevity with limitless funds for research
Read more“A growing interest in the field and even a fear of missing out on a revolutionary approach.”
Read moreAsgard Therapeutics AB announces the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
Read moreSmiLe Incubator company Asgard Therapeutics collaborates with Lund University and two European contract research organizations in the project REPRogramming tumors INTo immune cells: a revolutionary gene therapy to treat cancer. The three-year proposal was ranked #4 out of 644 European applications for Eurostars Cut off 15, and is thereby securing a grant of 2 million euros.
Read moreThe 2021 Merck EU Advance Biotech Grants Program aims to support emerging biotech companies pushing innovative drugs to the market by allowing grant recipients to receive free products and services.
Read moreAsgard Therapeutics project “Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC” in collaboration with Skåne University Hospital and Lund University was awarded with Sweden’s SWElife innovation grant.
Read moreCongrats to @AsgardThx and Filipe Pereira (@CellReproLab), winners of the 2020 ISMMS-KiiLN award, on their seed round and growing team! @MtSinaiPostdocs @MountSinaiAlum @IcahnMountSinai @ISMMSPostdocOff @MountSinai_IP #SINAInnovations http://shorturl.at/otJT5
Cristiana Pires CEO of Asgard is proud to participate in the US Camp promoted by the @MentorNordic (NOME) taking place in San Francisco, USA. Thank you @CALifeSciences for organizing the programme!
#collaboration #Asgard
https://nome.nu/
#ISSCR2022 has started! Exciting science coming!
Filipe Pereira Co-Founder and Head of Innovation at Asgard will be presenting at the @ISSCR in San Francisco, USA, on the 16th of June at 17:15-19:00 (GMT-7). Don’t miss this opportunity!
#TrojanDC #Immunotherapy
https://www.isscr.org/meetings-events/annual-meetings/isscr-annual-meeting-2022
The Asgard team today took part in helping to raise awareness for the @CancerResearch (CRI), Immunotherapy Month, as we wish to bring further awareness to this topic this month from all our members!
#immune2cancer #trojanDC
Invest in Skåne interviews our CEO @_CristianaPires about the support of @investinskane in the initial stages of @Asgardthx, leading to an almost mythical seed capital funding round, which closed in late 2021 at 6 million euros!
https://www.linkedin.com/posts/investinskane_investment-case-stories-activity-6935921062421409792-PueQ/?utm_source=linkedin_share&utm_medium=member_desktop_web
Come check out what @asgardthx has done with its website! Don’t miss the opportunity to have access to the latest publications, interviews, videos and updates from our team.
#Immunotherapy #FutureofHealthcare #Startupcompany #HealthcareInnovation
@MicheleTavecchio has joined Asgard Therapeutics as Senior Scientist to work on the In vivo validation of cell reprogramming technologies. Michele is a successful scientist with international acquired experience in the fields of Cancer Pharmacology and Therapy.
Our Co-Founder and Head of research Fábio Fiúza Rosa will be sharing and reflecting on Asgard Therapeutics key research and journey to date at Science After Work today at Medicon Village.
#innovationinhealthcare #asgardthx #Smile
Reprogramming Star Cristiana Pires unveils the career path that lead her to the stellar position of CEO and Co-founder at Asgard Therapeutics in this month issue of Cellular Reprogramming.
;